Table 1 Relationship between SHH expression and clinicopathologic characteristics in GC patients
Characteristic | N | SHH Expression | |||
|---|---|---|---|---|---|
Low(n = 69) | High(n = 48) | Χ 2 Value | P value | ||
Gender | |||||
Male | 71 | 41 (59.42 %) | 30 (62.50 %) | 0.113 | 0.444 |
Female | 46 | 28 (40.58 %) | 18 (37.50 %) | ||
Age (years) | |||||
<60 y | 74 | 43 (62.38 %) | 31 (64.58 %) | 0.062 | 0.479 |
≥ 60 y | 43 | 26 (37.62 %) | 17 (35.42 %) | ||
Location | |||||
Proximal | 14 | 10 (14.49 %) | 4 (8.33 %) | 1.973 | 0.578 |
Middle | 18 | 10 (14.49 %) | 8 (16.67 %) | ||
Distal | 59 | 32 (46.38 %) | 27 (56.25 %) | ||
More than 2 | 26 | 17 (24.64 %) | 9 (18.75 %) | ||
Tumor size | |||||
<5 cm | 67 | 37 (53.62 %) | 30 (62.50 %) | 0.911 | 0.223 |
≥ 5 cm | 50 | 32 (46.38 %) | 18 (37.50 %) | ||
Histologic type | |||||
Adenocarcinoma | 98 | 59 (85.51 %) | 39 (81.25 %) | 0.377 | 0.357 |
Others | 19 | 10 (14.49 %) | 9 (18.75 %) | ||
Bormann classification | |||||
1 | 6 | 4 (5.80 %) | 2 (4.17 %) | 0.476 | 0.924 |
2 | 24 | 15 (21.74 %) | 9 (18.75 %) | ||
3 | 69 | 39 (56.52 %) | 30 (62.50 %) | ||
4 | 18 | 11 (15.94 %) | 7 (14.58 %) | ||
Differentiation grade | |||||
Well | 26 | 19 (27.54 %) | 7 (14.58 %) | 2.924 | 0.232 |
Moderately | 66 | 48 (69.56 %) | 40 (83.33 %) | ||
Poorly | 25 | 2 (2.90 %) | 1 (2.08 %) | ||
pT staging | |||||
T1–2 | 28 | 10 (14.49 %) | 18 (37.50 %) | 8.231 | 0.004 |
T3–4 | 89 | 59 (85.51 %) | 30 (62.50 %) | ||
pN staging | |||||
N0 | 20 | 7 (10.14 %) | 13 (27.08 %) | 5.731 | 0.017 |
N1-3 | 97 | 62 (89.86 %) | 35 (72.92 %) | ||
pM staging | |||||
M0 | 104 | 66 (95.65 %) | 38 (79.17 %) | 7.789 | 0.006 |
M1 | 13 | 3 (4.35 %) | 10 (20.83 %) | ||
pTNM staging | |||||
I–II | 36 | 31 (44.93 %) | 5 (10.42 %) | 15.827 | <0.001 |
III–IV | 81 | 38 (55.07 %) | 43 (89.58 %) | ||